HLA-C and neoplasm: Vaccinating cancer patients against the mutanome involves the sequencing of the tumour’s genome, a comparison to the healthy tissue, and in silica prediction of relevant coding mutations capable of providing MHC-presented peptides before the design and production of the individualised mRNA vaccine through a process named MERIT (mutanome engineered RNA immunotherapy) [17,18].